PMID- 23192311
OWN - NLM
STAT- MEDLINE
DCOM- 20130910
LR  - 20211203
IS  - 1432-2072 (Electronic)
IS  - 0033-3158 (Linking)
VI  - 226
IP  - 2
DP  - 2013 Mar
TI  - Effect of angiotensin II on spatial memory, cerebral blood flow, cholinergic 
      neurotransmission, and brain derived neurotrophic factor in rats.
PG  - 357-69
LID - 10.1007/s00213-012-2913-8 [doi]
AB  - RATIONAL: Studies have shown the involvement of angiotensin II (Ang II) in 
      neurobehavioral aspects, but the exact role of Ang II in memory is still 
      ambiguous. OBJECTIVE: This study explored the effect of central Ang II on spatial 
      memory along with cholinergic neurotransmission, brain energy metabolism, 
      cerebral blood flow (CBF), and brain-derived neurotrophic factor (BDNF) in rats. 
      METHODS: Spatial memory was evaluated by Morris water maze (MWM) after Ang II 
      (ICV) administration in male Sprague-Dawley rats. CBF was measured by laser 
      Doppler flowmetry. Oxidative stress adenosine triphosphate (ATP), BDNF, 
      acetylcholinesterase (AChE), and acetylcholine (ACh) were estimated in the cortex 
      and hippocampus at 1, 24, and 48 h after Ang II administration. The effect of AT1 
      and AT2 receptor blocker (candesartan and PD123,319, respectively), AChE 
      inhibitor (donepezil), and antioxidant melatonin was studied on memory, CBF, and 
      biochemical parameters. RESULTS: Ang II caused spatial memory impairment by 
      affecting acquisition, consolidation, and recall in the MWM test along with a 
      significant reduction in CBF. Ang II significantly reduced ACh level and caused 
      oxidative stress in the rat brain 1 h post-injection. No significant change was 
      observed in BDNF, AChE, and ATP level. Candesartan and donepezil prevented Ang 
      II-induced memory impairment, reduction in CBF and ACh level. However, PD123,319 
      and melatonin failed to prevent Ang II-induced memory impairment but improved CBF 
      partially. CONCLUSION: This study suggests that Ang II, via the AT1 receptor, 
      affects spatial memory formation, CBF, and ACh level while AT2 receptor has no 
      significant role.
FAU - Tota, Santoshkumar
AU  - Tota S
AD  - Division of Pharmacology, CSIR-Central Drug Research Institute, Lucknow, Uttar 
      Pradesh, India.
FAU - Goel, Ruby
AU  - Goel R
FAU - Pachauri, Shakti Deep
AU  - Pachauri SD
FAU - Rajasekar, N
AU  - Rajasekar N
FAU - Najmi, Abul Kalam
AU  - Najmi AK
FAU - Hanif, Kashif
AU  - Hanif K
FAU - Nath, Chandishwar
AU  - Nath C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121129
PL  - Germany
TA  - Psychopharmacology (Berl)
JT  - Psychopharmacology
JID - 7608025
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Benzimidazoles)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Cholinesterase Inhibitors)
RN  - 0 (Imidazoles)
RN  - 0 (Indans)
RN  - 0 (Piperidines)
RN  - 0 (Pyridines)
RN  - 0 (Tetrazoles)
RN  - 11128-99-7 (Angiotensin II)
RN  - 130663-39-7 (PD 123319)
RN  - 8L70Q75FXE (Adenosine Triphosphate)
RN  - 8SSC91326P (Donepezil)
RN  - EC 3.1.1.7 (Acetylcholinesterase)
RN  - JL5DK93RCL (Melatonin)
RN  - N9YNS0M02X (Acetylcholine)
RN  - S8Q36MD2XX (candesartan)
SB  - IM
MH  - Acetylcholine/*metabolism
MH  - Acetylcholinesterase/metabolism
MH  - Adenosine Triphosphate/metabolism
MH  - Angiotensin II/*pharmacology
MH  - Angiotensin Receptor Antagonists/pharmacology
MH  - Animals
MH  - Benzimidazoles/pharmacology
MH  - Biphenyl Compounds
MH  - Brain-Derived Neurotrophic Factor/*metabolism
MH  - Cerebrovascular Circulation/*drug effects
MH  - Cholinesterase Inhibitors/pharmacology
MH  - Donepezil
MH  - Hippocampus/metabolism
MH  - Imidazoles/pharmacology
MH  - Indans/pharmacology
MH  - Male
MH  - Melatonin/pharmacology
MH  - Memory/*drug effects
MH  - Oxidative Stress/drug effects
MH  - Piperidines/pharmacology
MH  - Pyridines/pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Synaptic Transmission/*drug effects
MH  - Tetrazoles/pharmacology
EDAT- 2012/11/30 06:00
MHDA- 2013/09/11 06:00
CRDT- 2012/11/30 06:00
PHST- 2012/08/31 00:00 [received]
PHST- 2012/10/20 00:00 [accepted]
PHST- 2012/11/30 06:00 [entrez]
PHST- 2012/11/30 06:00 [pubmed]
PHST- 2013/09/11 06:00 [medline]
AID - 10.1007/s00213-012-2913-8 [doi]
PST - ppublish
SO  - Psychopharmacology (Berl). 2013 Mar;226(2):357-69. doi: 
      10.1007/s00213-012-2913-8. Epub 2012 Nov 29.